Compositions and doses of lymphotactin given in conjunction with vaccines to provide improved immune response
Methods of lymphotactin use as an adjuvant to boost mucosal immune responses to a vaccine antigen
Antibodies or the use of antibodies directed against CCL25 and CCR9 that propagate melanoma growth, migration, and/or invasion.
Antibodies or the use of antibodies directed against CXCL10 that mediate inflammation
Antibodies or the use of antibodies directed against CXCL13 and CXCR5 that propagate melanoma growth, migration, and/or invasion
Methods of milling nanoparticles containing a biologically active agent, at least one biopolymer, where coating contains at least one polymer or ligand
Antibodies or the use of antibodies directed against CXCL9 and CXCL11 that mediate inflammation
Antibodies or the use of antibodies directed against CXCL13 and CXCR5 to prevent and treat cancer and cancer cell migration.
Novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.
Antibodies or the use of antibodies directed against CCL25 that mediate inflammation
Antibodies or the use of antibodies directed against chemokines (CXCL9, CXCL10, CXCL11, and CXCL13) and chemokine receptors (CXCR3 and CXCR5) as agents against inflammatory disorders
Compositions comprising milled nanoparticles containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate
Antibodies or the use of antibodies directed against CCL25 and CCR9 to detect cancer and metastasis
CCL2-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CCR2-and CCR4-mediated disorders
Methods of formulating a pharmaceutical composition using milled nanoparticles of precise size containing an anti-cancer agent, polyethylene glycol, and starch, cellulose, collagen, lactose, or alginate
Chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates
Antibodies or the use of antibodies directed against CCL25 and CCR9 to prevent and treat cancer and cancer cell migration
CXCL13-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR5-mediated disorders.
CCL18-immunoglobulin fusion polypeptides and conjugates for targeted treatment of PITPNM3-, GPR30-, and CCR8 -mediated disorders.
CXCL12-immunoglobulin fusion polypeptides and conjugates for targeted treatment of CXCR4-mediated disorders.
Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
US20170280712A1 Notice of Allowance (6/28/2018)
Compositions and methods nanoformulations for plants